Medicinal Products

986. Deputy Paula Butterly asked the Minister for Health the measures being taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel–Lindau disease, in circumstances where clinicians warn that any delay risks irreversible neurological and functional decline; if compassionate or exceptional access pathways are available pending completion of national reimbursement pro…

1020. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE has undertaken, commissioned, or reviewed any health economic or cost-benefit analysis on the use of GLP-1 receptor agonist medicines, including tirzepatide and semaglutide, for obesity treatment and the prevention of type 2 diabetes; if so, the details and outcomes of any such analysis; and if not, whether sh…

1021. Deputy Ken O'Flynn asked the Minister for Health the current policy position of her Department regarding the reimbursement of GLP-1 receptor agonist medicines under the Drugs Payment Scheme; whether any review is under way to consider broader eligibility criteria; and the expected timeline for any decision on changes to reimbursement policy. [7677/26]

1022. Deputy Ken O'Flynn asked the Minister for Health whether her Department has assessed the potential impact of GLP-1 receptor agonist medicines on reducing the future incidence of type 2 diabetes, cardiovascular disease, and associated complications; whether such preventative outcomes are factored into medicines reimbursement decisions; and if she will outline how prevention-based savings are …

1023. Deputy Ken O'Flynn asked the Minister for Health what consideration has been given to the equity implications of high out-of-pocket costs for GLP-1 receptor agonist medicines; whether the Department has examined the risk of access being determined by ability to pay rather than clinical need; and if she will outline any measures under consideration to address this issue. [7679/26]

1037. Deputy Carol Nolan asked the Minister for Health if she will intervene to support the case of a person (details supplied) in urgent need of life-saving medication; and if she will make a statement on the matter. [7717/26]

1047. Deputy Ann Graves asked the Minister for Health the steps which are being taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel-Lindau disease where clinicians advise that delay risks irreversible loss of neurological and functional ability; whether compassionate or exceptional access mechanisms are available while national reimbursement processes are ongoin…

1053. Deputy Eamon Scanlon asked the Minister for Health the steps being taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel-Lindau disease where clinicians advise that delay risks irreversible loss of neurological and functional ability; whether compassionate or exceptional access mechanisms are available while national reimbursement processes are ongoing; the …

1058. Deputy Mark Wall asked the Minister for Health if she will provide access to a medicine for the urgent case of a person (details supplied). [7780/26]

1059. Deputy Mark Wall asked the Minister for Health the steps being taken to ensure urgent access to Welireg (belzutifan) for a young adult with Von Hippel-Lindau disease where clinicians advise that delay risks irreversible loss of neurological and functional ability; and the safeguards currently in place to protect such patients from avoidable permanent harm during administrative delays. [7781/…

1062. Deputy John Connolly asked the Minister for Health the steps being taken to ensure access to Welireg (belzutifan) for patients with Von Hippel–Lindau disease whose treating clinicians advise that delay risks irreversible neurological and functional decline; if compassionate or exceptional access mechanisms are available; and if she will make a statement on the matter. [7800/26]

1081. Deputy Pádraig O'Sullivan asked the Minister for Health the reason low-dose atropine (0.05%) eye drops for myopia control are difficult to obtain or totally unavailable (details supplied); if she will make provision for this medicine to be sourced for children who need them; and if she will make a statement on the matter. [7918/26]

1146. Deputy Grace Boland asked the Minister for Health the status of the proposed national rollout of the iSIMPATHY medication safety programme, which demonstrated improved patient outcomes and cost savings during its HSE pilot; the timeline for national implementation; and if she will make a statement on the matter. [8432/26]

1147. Deputy Grace Boland asked the Minister for Health her plans to strengthen national medication safety initiatives in line with the WHO “Medication Without Harm” programme; if she will report on progress in ensuring that every patient has access to clear medication information, including the medicines list recently incorporated into the Health App; and if she will make a statement on the matte…

460. Deputy Robert O'Donoghue asked the Minister for Health the steps that are being taken to ensure urgent access to the medication welireg (belzutifan) (details supplied); whether compassionate or exceptional access mechanisms are available while national reimbursement processes are ongoing; the safeguards currently in place to protect such patients from avoidable permanent harm during administr…

461. Deputy Martin Daly asked the Minister for Health the action her Department and the HSE have taken on the proposed introduction of a national programme for the safe disposal of unused medications in the community in line with EU Directive 2001/83/EC; if she will commit to pursuing this matter further with a view to establishing a safe, consistent and accessible return system through community …

184. Deputy Ryan O'Meara asked the Minister for Health for an update on the new framework agreements on the pricing and supply of medicines; and if she will make a statement on the matter. [6669/26]

188. Deputy David Cullinane asked the Minister for Health the contingency plan and guidance in place and issued by the HSE in response to the shortages of certain salbutamol products; the list of salbutamol products which are approved for reimbursement; whether each of these is in stock; the availability of substitute products for which a reimbursement price has not been agreed but which have been…

200. Deputy Marie Sherlock asked the Minister for Health the expenditure cost under the community drug scheme for continuous glucose monitoring (CGM) sensors with associated systems for each of the years 2023, 2024 and 2025; the number of patients availing of CGM sensors under the scheme for each year; the number of those patients with type 1 and type 2 diabetes; and if she will make a statement o…

217. Deputy Pádraig Rice asked the Minister for Health if a new agreement with respect to the pricing and supply of medicines contains any provisions which would see the procurement and use of pharmaceuticals manufactured by a company (details supplied) discontinued where alternatives exist; if not, to state whether this agreement will lead to an increase in the procurement of pharmaceuticals manu…

948. Deputy Louis O'Hara asked the Minister for Health if a person (details supplied) qualifies for reimbursement of expenses on saxenda injections; and if she will make a statement on the matter. [5637/26]

60. Deputy Ruairí Ó Murchú asked the Minister for Health the reason ostomy products are not included on the long-term illness scheme; if ostomy products were ever considered for the long term illness scheme; if so, when; and if she will make a statement on the matter. [3641/26]

116. Deputy John Lahart asked the Minister for Health for an update on the accessibility of the drug givinostat for patients with Duchenne muscular dystrophy. [5070/26]

510. Deputy Ciarán Ahern asked the Minister for Health to intervene in the case of a person (details supplied) to ensure that they can access vital medicines; and if she will make a statement on the matter. [5112/26]

272. Deputy William Aird asked the Minister for Health the steps being taken to introduce a formal compassionate use programme in Ireland for orphan drugs, in light of the fact that several EU member states already have such programmes allowing patients early access to potentially life-saving treatments prior to full market authorisation; when such a programme will be established to ensure patient…